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Abstract
Background: Ribosome display technology has provided an alternative platform technology for the development of novel
low-cost antibody based on evaluating antibiotics derived residues in food matrixes.
Methodology/Principal Findings: In our current studies, the single chain variable fragments (scFvs) were selected from
hybridoma cell lines against sulfadimidine (SM2) by using a ribosome library technology. A DNA library of scFv antibody
fragments was constructed for ribosome display, and then mRNA–ribosome–antibody (MRA) complexes were produced by
a rabbit reticulocyte lysate system. The synthetic sulfadimidine-ovalbumin (SM2-OVA) was used as an antigen to pan MRA
complexes and putative scFv-encoding genes were recovered by RT-PCR in situ following each panning. After four rounds of
ribosome display, the expression vector pCANTAB5E containing the selected specific scFv DNA was constructed and
transformed into Escherichia coli HB2151. Three positive clones (SAS14, SAS68 and SAS71) were screened from 100 clones
and had higher antibody activity and specificity to SM2 by indirect ELISA. The three specific soluble scFvs were identified to
be the same molecular weight (approximately 30 kDa) by Western-blotting analysis using anti-E tag antibodies, but they
had different amino acids sequence by sequence analysis.
Conclusions/Significance: The selection of anti-SM2 specific scFv by in vitro ribosome display technology will have an
important significance for the development of novel immunodetection strategies for residual veterinary drugs.
Citation: Qi Y, Wu C, Zhang S, Wang Z, Huang S, et al. (2009) Selection of Anti-Sulfadimidine Specific ScFvs from a Hybridoma Cell by Eukaryotic Ribosome
Display. PLoS ONE 4(7): e6427. doi:10.1371/journal.pone.0006427
Editor: Cameron Neylon, University of Southampron, United Kingdom
Received April 19, 2009; Accepted June 19, 2009; Published July 29, 2009
Copyright:  2009 Qi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Program for Cheung Kong Scholars and Innovative Research Team in University, National Natural Science Fund of Key
Program and ‘‘863’’ Fund (Nos.IRT0866, Nos.30830082 and 2008AA10Z423) of China. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sjz@cau.edu.cn
Introduction
Sulfadimidine, derivatives of r-aminobenzenesulfonamide, is
widely used in veterinary and human medicine for prophylactic
and therapeutic purposes. It is also used as additive of animal feed
due to their growth promotion properties. However, the proper
withdrawal periods need to be done before slaughtering or milking
in the medicated animals. Otherwise the meat and milk from these
animals may be contaminated with residual SM2, leading to
adverse effects (toxic action and resistance) in human. In the USA,
European Union and Canada, the maximum residue limit (MRL)
of total sulfonamides in edible tissues is 100 mg/kg, and 20 mg/kg
in Japan [1–3].
The monitoring programs, especially immunochemical screen-
ing methods have been widely used to evaluate antibiotics derived
residues in food matrixes. Current conventional methods for the
analysis of sulfonamides derived residue are microbiological tests
and analytical methods, such as thin-layer chromatography or
high-performance liquid chromatography. However, these meth-
ods require well equipped laboratory, trained personnels, high
capital expenditure and time-consuming sample preparation steps.
Immunochemical assays such as enzyme linked-immunosorbent
assay (ELISA) are simple, rapid, sensitive, specific, and generally
cost-effective for large sample loads[4]. A number of immuno-
chemical assays have been developed to screen sulfonamide [5–7].
However, Current sulfonamides immunochemical assays use
conventional polyclonal (PAb) and monoclonal antibodies
(MAb). PAbs are the easiest and quickest to produce, but they
are not single molecular entities and sometimes cause nonspecific
reactivity. MAbs are single molecular entities, and multiple clones
are available for selection in the development process, but the
preparation of MAb is more complex, and expensive cell culturing
facilities are required for large scale production [8].
Recently, recombinant antibody display technology has provid-
ed an alternative platform technology for the development of novel
low-cost antibody based biotherapeutics and biological detection
[9,10]. One of the most remarkable molecules of recombinant
antibodies is the single chain variable fragment (scFv), which is
made by connecting the variable heavy chain with light chain
region. This structure still retains the binding properties of classical
antibody. ScFv technology is a new strategy for developing
improved immunodetection tests for veterinary drugs [11,12].
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6427ScFv antibodies can be generated by phage display or ribosome
display technologies. Although phage display represents a
considerable progress compared to hybridoma technology, it is
still not a perfect technique. First, the necessary transformation
step limits the library size. Secondly, the selection in the context of
the host environment cannot be avoided and their growth
disadvantage or toxicity for Escherichia coli possibly lead to a loss
of potential candidates. Furthermore, difficulties in eluting phages
carrying antibodies with very high affinity may be encountered
[13,14]. Ribosome display, created by Mattheakis et al and
modified by Hanes and Plu ¨ckthun as well as He and Taussig, is a
robust tool for the isolation of specifically binding antibody
fragments and non-immunoglobulin scaffolds [15–21]. It is based
on the formation of a mRNA-Ribosome-Antibody(MRA) ternary
complexs during in vitro expression. In the ribosome display, those
of the limitations of phage display are circumvented by utilizing a
cell-free transcription, translation and panning system. A larger
capacity and further diversity of libraries will be built up and the
random mutations can be introduced by PCR. It has exceptional
strength in molecular evolution and affinity maturation. By using
this novel technology, it is currently possible to select and evolve
the high-affinity antibodies [20,22,23].
In this study, we hypothesize that scFvs specific for anti-
sulfadimidine from a hybridoma cell can be produced and the
affinity-matured efficiently using ribosome display technology and
envisage that these unique scFvs will be valuable diagnostics in
agriculture and the food industry. We hope that this study would
provide a pathway for the development of a novel immunoassay
on residual SM2 detection by using recombinant antibody.
Results and Discussion
Antibody library construction
VH and VL fragments were amplified by RT-PCR from
hybridoma cell lines secreting anti-SM2 MAb and assembled into
full-length scFvs library with the (Gly4Ser)3-linker sequence. The
amplified VH and VL fragments were the expected size (about
340 bp and 325 bp). (Fig. 1). The assembled approximate 0.8 kb
full-length scFv fragments were used for the construction of
templates of ribosome display.
Ribosome display and in situ RT-PCR recovery scFv
The gel-purified scFv fragments were digested and ligated into
the vector pRDV. The ligation product was directly used as a
template for the amplification of initial ribosome display library.
The original scFv library was subjected to in vitro transcription and
translation using TNT T7 Quick for PCR DNA kit to generate
ternary MRA complexes. The target antigens were immobilized
on microtiter plates. The selected specific scFv fragment based on
mRNA of retained MRA complexes bound to SM2-OVA at the
plate wells was recovered after several washing with increasing
stringency during the individual rounds of selection by in situ RT-
PCR and SP-PCR. The obtained products were applied to the
affinity maturation or next round of panning. Each cycle of
ribosome display was performed under the same conditions
including the concentration of target antigens and the spanning
washing time. As a whole, four cycles of selection on SM2-OVA, as
well as one round of affinity maturation were performed. The
panning progress was monitored by examining the intensity of SP-
PCR products (approximately 1.1 kb) on agarose gel–electropho-
resis. The quantity of SP-PCR products continually increased
during the next rounds of panning. Based on the result of SP-PCR,
enrichment of specific scFvs was clearly confirmed. Meanwhile, no
band was observed PBS-coated wells or when the untranslated
mixture was used. (Fig. 2).
Here, we performed eukaryotic ribosome display by using an in
vitro coupled transcription/translation system. These processes,
based on the E.coli.S30 and rabbit reticulocyte systems, had been
described in previous studies [19,24–29]. We carried out the
coupled transcription/translation steps, which were conducted by
Figure 1. Agarose gel electrophoresis of amplified VH chain, VL chain and assembled scFv fragments. Lane M: 100 bp plus DNA marker,
lane 1: VH fragments, lane 2: VL fragments, lane3: about 800 bp assembled scFv fragments.
doi:10.1371/journal.pone.0006427.g001
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process, the translation was directly completed in tandem,
potentially resulting in greater functional expression of scFvs
antibodies [25]. Meanwhile, the rabbit reticulocyte system has
lower RNase activity than an E.coli.S30 ribosome display system,
leading to a less complicated selection condition [26]. Moreover,
eukaryotic conditions may improve the translation or folding
efficiency of some proteins. Then in our work, the eukaryotic
ribosome display with coupled transcription/translation was used
for selection and evolution of specific antibody.
In addition, the principal distinction between the E.coli.S30 and
rabbit reticulocyte systems is in the DNA recovery step. In the
E.coli.S30 system, a chemical disruption procedure (EDTA) is
introduced to dissociate the ribosome and release the mRNA,
which is then purified before RT-PCR. Although this procedure
efficiently isolates mRNA from E.coli ribosome complexes, it gives
a relatively poor recovery from those generated by rabbit
reticulocyte lysate [25,27], so that it cannot be applied directly
to eukaryotic MRA complexes. We introduced the in situ RT-
PCR procedure in which an internal primer is used for performing
reverse transcription directly on the eukaryotic ribosome com-
plexes without their disruption or mRNA isolation [28,29]. Not
only does this simplify the recovery process, but it also avoids losses
incurred in complex disruption. This procedure has been proved
to be efficient and reliable in cDNA recovery in other studies
[25,28,30]. The ineffectiveness, in the in situ procedure, of a
primer that recognizes the 39 end of the mRNA, compared with
the efficient use of one hybridizing upstream, is consistent with the
interpretation that the ribosome is stalled at the end of the mRNA,
which is consequently unavailable at the initiation of reverse
transcription. The possibility of the 39 end of the mRNA being
degraded, as has been speculated, has been excluded by showing
that mRNA released from the ribosome complexes by EDTA,
although low in yield, could be recovered and amplified by the 39
terminal primer with similar efficiency to the internal primer. The
single-primer RT-PCR procedure presented here is a refinement
of the in situ DNA recovery method. It is based on the finding that
single-primer PCR technology is capable of amplifying efficiently
individual molecules of dsDNA fragments carrying identical
flanking sequences at each end [31]. We have adapted this
concept to in situ RT-PCR recovery by producing single-stranded
cDNAs with complementary flanking 59 and 39 terminal
sequences, so that PCR can be performed using a single consensus
primer (KZ) to amplify the resultant cDNA templates. The
method involves a new reverse transcription primer (RT-kz), the 39
end of which hybridizes ,60 nt upstream of the 39 terminus of the
mRNA, and the 59 end includes a consensus sequence from the
transcription start to the translation initiation site. The in situ
recovery method, using RT-PCR on an mRNA template that has
not been prereleased from the ribosome, provides high sensitivity
in a simple procedure and avoids sample loss.
The Characterization of soluble scFv
The selected specific scFv fragment after the fourth round was
ligated with the expression vector pCANTAB5E for soluble scFvs
expression. After electrotransformation, around 100 colonies from
the selected library were isolated and soluble proteins of these
clones were expressed using the nonsuppressor strain E.coli
HB2151. The periplasmic extracts from individual clones were
tested by indirect ELISA. The result showed that few clones
showed positive to SM2 in ribosome-ELISA before panning (Fig.
S1), however, several clones from the fourth selected library had a
good conjugation activity to specific SM2-OVA. Among these
clones, the three clones (SAS14, SAS68, SAS71) exhibiting the
highest ELISA signals to SM2-OVA were not significantly
different to the anti-SM2 MAb (Fig. 3). The result suggested that
the conjugation activity of scFvs was similar to that of parent MAb.
The three specific soluble scFvs were confirmed by SDS-PAGE
and Western-blotting analysis using anti-E tag antibodies.
Approximately 30 kDa scFv protein was expressed from each of
the three selected clones in the periplasmic extract sample
compared to negative control (Fig. 4).
Figure 2. Selection and amplification of anti-SM2 scFv gene over four rounds of ribosome display. After selection, the selected product
was amplified by SP-PCR and the SP-PCR products were analyzed by agarose gel electrophoresis. lane M: DL2000 DNA marker, lane 1: preliminary
translation mixture selected on a PBS-coated well, lane 2: translation mixture selected on a OVA-coated well, lane 3: recovered band from the first
ribosome display, lane 4: recovered band from the second round, lane 5: recovered band from the third cycle, lane 6: recovered band from the fourth
selected library.
doi:10.1371/journal.pone.0006427.g002
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three scFvs and complementary determining regions (CDR) were
shown in Fig. 5. By using the DNA sequences, the VH and VL
gene families of the scFvs were designated based on Werner
Mu ¨ller’s database (DNAPLOT software). The heavy chains of
scFvs SAS68 and SAS71 belong to the VH1 gene family and that
of SAS14 belongs to the VH2 gene family. The light chains of
clones SAS68 and SAS71 belong to the Vk IGKV12/13 subgroup
and that of SAS14 belongs to the Vk IGKV4/5 subgroup.
Sequencing alignment by the Vector NTI software program
showed that the VH of the clones SAS68 and SAS71 have very
similar sequences (90.44% homology) and the VL of SAS14,
SAS68 and SAS71 shared 82.81% homology. Although the
linking sequence of scFv SAS71 showed some mutations, these did
not influence protein structure obviously. This indicated that a
random mutation was induced by the second ribosome display,
but mutation affected scFv structures were selected. Sequencing
data indicated that we succeeded in achieving our desired goals of
library generation with the affinity maturation method.
In vitro selection cycles enable the introduction of further diversity
every iteration, providing a means of protein evolution. Thus,
ribosome display and similar methods are routes to increased
diversity, and improve selection and a range of potentially novel
molecules [32]. We carried out the affinity maturation by using
error-prone PCR (EP-PCR) and staggered extension process (StEP)
shuffling in tandem during the second round of ribosome display.
The enrichment of specific scFvs was confirmed by the SP-PCR
recovery band from each ribosome display cycle and the binding
activity of scFvs from the fourth selected antibody library,
respectively. After four rounds of ribosome display, three scFvs
with high specificity and affinity were successfully selected. It
showed that the slightly modified ribosome display technology was
feasible for selection of specific scFvs against SM2.
Conclusions
In this report, we demonstrated the generation of anti-SM2
specific scFvs from hybridoma cell lines by eukaryotic ribosome
display. Since ribosome display technology was first reported in
1994 [18], some early studies suggested antibody selection from a
library using ribosome display[25,28,29,32,33]. However, there
have been few reported about selection of scFvs against SM2.
Therefore, our work is significant to be an example for selecting
specific scFvs against veterinary drugs by eukaryotic ribosome
display. As an alternative to antiserum or MAb, the selected
specific scFvs with high affinity can be used as detection reagent of
SM2 in foodstuffs in the future. In addition, this work provides a
novel pathway for the development of a rapid, sensitive and multi-
residue immunoassay analysis technology for veterinary drugs
detection with using recombinant antibody.
Materials and Methods
Plasmids, Strains and Reagents
All reagents used in the study were commercially available and
were of reagent grade or better. All restriction enzymes and DNA
modification enzymes were of molecular biology grade. DH5a and
Figure 4. Detection of soluble scFvs in periplasmatic extracts
by Western Blot. M: low molecular weight protein marker, lanes1–3:
Periplasmatic extracts of scFvs SAS14, SAS68, and SAS71.
doi:10.1371/journal.pone.0006427.g004
Figure 3. Clones were isolated from the fourth selected antibody library. Each clone was expressed for producing soluble scFv, and the binding
activity of each scFv and the anti-SM2 MAb (positive control) was determined by ELISA (in triplicate). The error bars represent the standard deviation.
doi:10.1371/journal.pone.0006427.g003
SM2,ScFvs,Ribosome Display
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ribosomedisplayvector(pRDV)wasobtainedasa gift fromthelabof
Prof. Andreas Plu ¨ckthun (Biochemisches Institut, Universita ¨tZu ¨rich,
Switzerland) [16]; The phagemid pCANTAB5E was from Amer-
sham Biosciences; The bacterial host used for cloning and expression
was the non-suppressor strain -E. coli HB2151, which was a gift from
the lab of Prof. Yuanming Sui (Food Quality and Safety Research
Institute, South China Agriculture University, P. R. China,); TNT
T7 Quick for PCR DNA kit (rabbit reticulocyte cell free extract) was
from Promega; Goat anti-E-Tag Antibody Affinity Purified HRP
conjugated was purchased from Bethl Laboratories Inc.
Construction of scFv library
Total RNA was extracted from 10
7 Hybridoma cells produced
previously by He et al [34] that secreted monoclonal antibody against
SM2 by using SV Total RNA Isolation System (Promega, USA).
About 0.5 mg of RNA was reverse transcribed by Oligo dT-Adaptor
primers of the first-strand cDNA synthesis kit (TaKaRa, JAPAN).
cDNA encoding the mouse variable heavy (VH) and light (VL)c h a i n s
were amplified by RT-PCR with degenerated immunoglobulin PCR
primers (35 cycles at 94uC for 30 s, 55uC for 30 s and 72uCf o r
1 min). A complementary (Gly4Ser)3-linker was added by a re-
amplification. The full-length scFvs were assembled by using splicing
overlap extension PCR. The purified products were cloned into the
vector pRDV to add a 59-T7-promotor and ribosome binding site
and 39-spacer region (Fig. 6). The templates of ribosome display
were amplified directly from the ligation mixture [35]. The primers
used in the PCR amplification were shown in Table 1.
In vitro transcription and translation
Eukaryotic ribosome display was conducted by a modified
method, which was reported previously [24,26,36]. Briefly, 50 ml
Figure 5. Alignment of the amino acid sequence of selected specific anti-SM2 scFvs. CDRs and the (Gly4Ser)3 linker are boxed. The regions
of CDR1-CDR3 were deduced according to Kabat database.
doi:10.1371/journal.pone.0006427.g005
Figure 6. Construction of the template of ribosome display. In this generalized construct for ribosome display, the gene of interest is flanked
by a 59sequence with the T7 promoter (T7) and eukaryotic translation initiation (Kozak) sequence, and a tolA domain is attached at the 39end as a
spacer. The stop codon is removed to ensure stalling of the ribosome at the end of translation. X indicates removal of the stop codon.
doi:10.1371/journal.pone.0006427.g006
SM2,ScFvs,Ribosome Display
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quick for PCR mix, 0.02 mM methionine and 1 mM Mg acetate,
was set up in a siliconized tube with 100–700 ng purified PCR
porducts. After incubation at 30uC for 60 min, the following
reagents were added: 60 units DnaseI (TaKaRa, JAPAN), 7 ml
106DNase I digestion buffer(400 mM Tris/HCl, pH 7.5, 60 mM
MgCl2, 100 mM NaCl) and adjusted the volume to 70 ml with
dH2O. The incubation continued for another 20 min and then the
digested product was diluted with 210 ml of cold PBS, containing
5 mM magnesium acetate [28,29].
Affinity selection and in situ RT-PCR Recovery
Microtiter plate was coated at 4uC overnight with 100 mlo f
Avidin solution (0.066 mM in PBS), and then washed with PBS for
three times and blocked with blocking buffer PBSB (PBS with 1%
(w/v) BSA) for 2 h at room temperature (RT). After another PBS
washing for three times, the plate was coated with 100 ml of Biotin-
N-hydroxy-succinimide ester-sulfadimidine-ovalbumin (BNHS-
SM2-OVA) at 4uC overnight. The coated plate was subsequently
washed by ice-cold washing buffer (PBS with 0.05 % (v/v) Tween
20 and 5 mM magnesium acetate) for three times, and then placed
on ice for at least 10 min. 100 ml the prepared TNT translation
mixture containing the MRA ternary complexes was added to an
antigen-coated well and incubated at 4uC for 2 h with gentle
vibration. Followed three times wash with cold washing buffer and
two times quick wash with ice-cold RNase-free water, in situ
Single-Primer RT-PCR Recovery was performed in the plate wells
carrying selected MRA complexes using PrimeScript
TM Reverse
Transcriptase (TaKaRa). In brief, 12 ml of solution A mixture,
containing 1 ml Primer RT-kz (10 mM), 2 ml dNTP (10 mM) and
9 ml RNase-free water, was added into each MRA-bound well.
After incubating at 48uC for 5 min and at least 30 s on ice, the
following reagents were added into each well: 200 units Prime-
Script
TM Reverse Transcriptase, 20 units Rnase Inhibitor, 5 mM
DTT, 4 ml5 6PrimeScript
TM buffer (250 mM Tris/HCl, pH 8.3,
15 mM MgCl2, 375 mM KCl) and adjusted the volume to 20 ml
with RNase-free water. The plate was incubated at 42uC for
45 min followed by 5 min at 85uC. The mixture cooled to room
temperature was then transfered to a fresh tube for subsequent
single-primer PCR (SP-PCR) using primer KZ. A further PCR
step was introduced to regenerate the full-length construct
avoiding shortening of the DNA fragment, compared to the
original fragment [29]. The primers used in the PCR amplification
were shown in Table 1. The purified PCR products were used for
the next round of ribosome display or cloned into E. coli HB2151
for expression.
Affinity maturation
The selected scFvs of first cycle were subjected to PCR-based
random mutagenesis by using the error-prone PCR and staggered
extension process (StEP) shuffling in tandem, according to the
protocols described by Cadwell [37] and Zhao[38] to generate the
initial mutant ribosome library of anti-Sulfanilamides scFvs. EP-
PCR reactions were carried out under the following conditions,
hereafter referred to as standard: 10 ng of DNA template,
106PCR buffer (Mg
2+ Free, TaKaRa), 10 mM of each dNTP
(dATP : dTTP=dGTP : dCTP=1 : 5), 10 mM of both primers
(VHForNcoI and VLRevHindIII), 25 mM MgCl2 and 2.5 U Taq
DNA polymerase (TaKaRa) in 50 ml volume. PCR reactions were
performed in an ABI thermocycler (Applied Biosystems Inc.) for
30 cycles: 1 min at 94uC, 1 min at 45uC and 2 min at 72uC,
followed by 7 min extension at 72uC. Then the StEP shuffling was
performed under the following conditions (5 min at 95uC, 80
cycles of 30 s at 94uC, and 5 s at 55uC, 5 min at 72uC), the StEP
shuffling reactions contained (50 ml final volume): 10 ng of the
DNA products of EP-PCR, 106PCR buffer (Mg
2+ Plus, TaKaRa),
10 mM of dNTP mixtures, 10 mM of both primers (VHForNcoI
and VLRevHindIII), 2.5 U Taq DNA polymerase (TaKaRa) and
dH2O. The purified StEP shuffling products were used for the
third round of ribosome display. The mutant repertoire was
panned against target antigen as described above. One cycle of
affinity maturation was performed.
Cloning and expression of scFv
After four selections, the obtained scFv fragment was amplified
with forward primer scFvForSfiI with the SfiI restriction site
(underlined) and reverse primer scFvRevNotI with the NotI
restriction site (underlined). The primers used in the PCR
Table 1. Synthesized oligonucleotides for the construction of scFv and ribosome display library.
Primer name sequence
VHFor AGATCTAGAGAATTCTGAGGAGACGGTGACCGTGGTCCCTTGGCCCCAG
VHRev AGATCTAGAAAGCTTAGGTCAAGCTGCAGCAGTCAGG
VLFor GGATACAGTTGGTGCAGCATC
VLRev GACATCCAGCTGACTCAGTCT
VHForNcoI CATGCCATGGATGGCCGTCAAGCTGCAGCAGTCAGGA
VHLinkRev ACCACCGGATCCGCCTCCGCCTAGATCTAGAGATTCTGAGGAGA
VLLinkFor GGAGGCGGATCCGGTGGTGGCGGATCTGGAGGTGGCGGAAGCGACATCCAGCTGACTCAGTC
VLRevHindIII CCCAAGCTTGGATACAGTTGGTGCAGCATC
T7B-kz GCAGCTAATACGACTCACTATAGGAACAGACCACCATGGCCGTCAAGCTGCAGCAG
tolAk CCGCACACCAGTAAGGTGTGCGGTTTCAGTTGCCGCTTTCTTTCT
RT-kz GAACAGACCACCATGCTGCTTCTGCCGCTTCC
KZ GAACAGACCACCATG
scFvForSfiI GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCCGTCAAGCTGCAGCAGTCAGGA
scFvRevNotI GAGTCATTCTGCGGCCGCGGATACAGTTGGTGCAGCATC
The underlined sequence indicates the NcoI, HindIII, SfiI and NotI restriction site for cloning.
doi:10.1371/journal.pone.0006427.t001
SM2,ScFvs,Ribosome Display
PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6427amplification were shown in Table 1. The amplified product were
digested with SfiI and NotI, then ligated with the vector
pCANTAB5E by using a T4 DNA ligase (Promega, USA). The
ligated products were transformed into E.coli HB2151 and the
soluble scFv protein was expressed from each clone[39]. In brief,
single colonies were grown in 5 ml of 26YT medium with
ampicillin (100 mg/ml) and glucose (0.1 % (w/v)) to an
OD600=0.6 at 30uC/250 r.p.m, and induced by the addition of
IPTG (final concentration 1 mM) overnight at 30uC/180 r.p.m.
The cells were pelleted at 4uC/4000 r.p.m for 10 min, and re-
suspended in 0.5 ml ice-cold 16TES buffer (0.2 M Tris/HCl
(pH 8.0), 0.5 mM EDTA, 0.5 M sucrose) and 0.75 ml ice-cold 1/
56TES buffer. After incubation on ice for 40 min, the cells were
pelleted at 4uC/12000 r.p.m for 20 min, and the supernatant was
retained as periplasmic extracts with the soluble scFvs. The
expressed soluble scFvs were detected by using anti-E tag
monoclonal antibody, since the pCANTAB5E vector contains
an additional sequence encoding the E-tag.
ELISA assays
To screen anti-SM2 specific scFvs, the expressed soluble scFvs
were analyzed by indirect ELISA. Microtiter plates were coated
with 100 ml of sulfadimidine-ovalbumin (SM2-OVA, 10 mg/ml in
PBS) overnight at 4uC. Plates were washed with washing buffer
and the blocking buffer (4 % (w/v) BSA in PBS, pH 7.4) was
subsequently added at 37uC for 1 h with gentle shaking. Blocked
plates were washed and 100 ml of periplasmic extracts diluted 1:1
with PBSB were titrated followed by 1 h incubation at 37uC.
Detection was performed with an HRP-labelled goat anti-E-tag
antibody (1:10000 dilution with blocking buffer). Plates were
developed with TMB-detection-solution and read at OD450 nm.
Immunoblot analysis of scFv expression
Periplasmic extracts from selected anti-sulfadimidine producing
clones were subjected to SDS-PAGE on a 12 % polyacrylamide
gel and Western blot. After SDS-PAGE, the gel was transferred
onto a nitrocellulose membrane. The transblotted membrane was
blocked for 1 h with a blocking buffer (4 % (w/v) BSA in PBS,
pH 7.4) and then incubated with anti-E-tag antibody HRP
conjugated (1:2000) for 2 h at RT. 4-CN (4-chloro-1-naphthol,
Sigma) was used as a peroxidase substrate to visualize the
immunoreactivity.
Sequence analysis
Plasmid DNA from anti-sulfadimidine producing clones was
isolated from E. coli HB2151 using the QIAEX II gel extraction kit
(QIAGEN). The scFv DNA was sequenced on both strands with
the pCANTAB5E sequence primer set using an ABI Perkin Elmer
373A automated DNA sequencer.
Supporting Information
Figure S1 Clones were isolated from the unselected antibody
library. Each clone was expressed for producing soluble scFv, and
the binding activity of each scFv and the anti-SM2 MAb (positive
control) was determined by ELISA (in triplicate). The error bars
represent the standard deviation.
Found at: doi:10.1371/journal.pone.0006427.s001 (0.46 MB TIF)
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